Share

March 2021; 8 (2) ArticleOpen Access

Amyotrophic Lateral Sclerosis Survival Associates With Neutrophils in a Sex-specific Manner

Benjamin J. Murdock, Stephen A. Goutman, Jonathan Boss, Sehee Kim, Eva L. Feldman
First published February 2, 2021, DOI: https://doi.org/10.1212/NXI.0000000000000953
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
815

Share

Article Information

vol. 8 no. 2 e953
DOI: 
https://doi.org/10.1212/NXI.0000000000000953
PubMed: 
33531377
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received August 13, 2020
  • Accepted in final form November 13, 2020
  • First Published February 2, 2021.
Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Benjamin J. Murdock, PhD (murdockb{at}med.umich.edu),
    2. Stephen A. Goutman, MD, MS,
    3. Jonathan Boss, BS, MS (bossjona{at}umich.edu),
    4. Sehee Kim, PhD (seheek{at}umich.edu) and
    5. Eva L. Feldman, MD, PhD, FAAN, FANA (efeldman{at}med.umich.edu)
  1. Benjamin J. Murdock, PhD (murdockb{at}med.umich.edu),
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Rush University Medical Center, honorarium for guest speaking RE: immunology in ALS

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) Method of use patent; repurposing JAK/STAT inhibitors for use in treating ALS

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Stephen A. Goutman, MD, MS,
    3. Scientific Advisory Boards:

    1. (1) Biogen (2) IFT Pharma (3) Watermark Research Partners

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH/NIEHS, K23ES027221, PI, 2017-present, (2) CDC/ATSDR, Contract # 200-2013-56856, Co-Investigator, 2013-2017, (3) CDC/ATSDR, R01 TS000289-01, Co-Investigator, 2018-present, (4) NIH/NIEHS, R01ES030049, Co-Investigator, 2020 - present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Target ALS, (2) ALS Association

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. (1) Listed as an inventor on a patent held by University of Michigan titled "Methods For Treating Amyotrophic Lateral Sclerosis" for targeting NK cells.

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Jonathan Boss, BS, MS (bossjona{at}umich.edu),
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. National Institutes of Health, Grant Number U24 AG066528-01. PI of overall grant is Dr. Stacy Drury, of which I will receive a $4,000 honorarium at the end of 2020 to fund a project that I am a co-PI on. The project is looking at the possible role of environmental exposures in explaining Black/White discrepancies in telomere length.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Sehee Kim, PhD (seheek{at}umich.edu) and
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Eva L. Feldman, MD, PhD, FAAN, FANA (efeldman{at}med.umich.edu)
    6. Scientific Advisory Boards:

    1. (1) Peripheral Neuropathy Association, Board Member, 1996-present (2) American Society for Experimental NeuroTherapeutics (ASENT), Board of Directors Member, 2003-present (3) The Foundation for Peripheral Neuropathy, Scientific Advisory Board Member, 2008-present (4) Stem Cell Michigan, Board Member, 2008-present (5) Peripheral Nerve Society Diabetes Neuropathy Consortium Board of Directors Member, 2018-present

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Current Opinion in Neurology, Editorial Board member, 2012-present (2) Journal of the Peripheral Nervous System, Editorial Board member, 2012-present (3) Experimental Neurology, Editorial Board member, 2012-present (4) Nature Neurology, Editorial Board member, 2012-present (5) Neurobiology of Disease, Editorial Board member, 2012-present (6) NeuroRx (Journal of the American Society of Neurotherapeutics), Editorial Board member, 2012-present (7) Journal of Neurology, Neurosurgery and Psychiatry, Editorial Board member, 2013-present (8) JAMA Neurology, Editorial Board member, 2014-present (9) Oxford University Press, Contemporary Neurology Series (CNS), Editor-in-Chief, 2016-present (10) Scientific Reports, Editorial Board member, 2018-present (11) The Lancet Neurology, Editorial Board member, 2019-present

    Patents:

    1. (1) Listed as an inventor on a patent held by University of Michigan titled "Methods For Treating Amyotrophic Lateral Sclerosis" for treating ALS using JAK/STAT inhibitors.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Novartis, consultant in 2019 (ended)

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. (1) American Neurological Association, Chair of the Nominating Committee, 2017 - 2019 (2) National Academy of Medicine, Strategic Planning Committee, 2016-present (3) National Academy of Medicine, Vice Chair of Section 07, 2018-2019 (4) National Academy of Medicine, Chair of Section 07, 2020-present (5) National Academy of Medicine, Membership Committee, 2020-present

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH, R21 NS102960, PI, 04/15/2018 – 03/31/2020 (2) NIH, R01 ES030049, PI, 01/01/2020 – 12/31/2024 (3) NIH, U24 DK115255, PI, 11/01/2019 – 10/31/2020 (4) NIH, R21 NS102924, PI, 09/01/2018 – 08/31/2020 (5) NIH, U01 AG057562, PI, 08/15/2018 – 07/31/2021 (6) NIH, T32 NS007222, PI/preceptor, 07/01/2017 – 06/30/2022 (7) NIH, U2C DK110768, Co-I, 08/02/2016 – 06/30/2021 (8) NIH, R24 DK082841, PI, 08/01/2016 – 07/31/2021 (9) NIH, R01 DK107956, PI, 03/01/2016 – 02/28/2021 (10) NIH, R01 DK108173, site PI, 09/30/2015 – 09/29/2020 (11) NIH, R01 GM13984201, Co-I, 09/21/2020 – 08/31/2021 (12) CDC/ATSDR, R01 TS00289, PI, 09/30/2018-09/29/2021 (13) CDC/ATSDR, 200-2013-56856, PI, 09/01/2013 – 08/31/2017

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Novo Nordisk Foundation, NNFOC0011633, 05/01/2015 – 04/30/2021 (2) Juvenile Diabetes Research Foundation, 5-COE-2019-861-S-B, 10/01/2019 – 09/30/2024

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (B.J.M., S.A.G., E.L.F.), and Department of Biostatistics (J.B., S.K.), School of Public Health, University of Michigan, Ann Arbor.
  1. Correspondence
    Dr. Goutman sgoutman{at}med.umich.edu
View Full Text

Article usage

Article usage: March 2021 to March 2023

AbstractFullPdfSource
Feb 202180703104Highwire
Mar 202123926163Highwire
Apr 202132518053Highwire
May 202129626887Highwire
Jun 202120812656Highwire
Jul 2021148629Highwire
Aug 20211111130Highwire
Sep 2021129017Highwire
Oct 2021118131Highwire
Nov 2021116831Highwire
Dec 202165717Highwire
Jan 20227609Highwire
Feb 2022315322Highwire
Mar 2022207217Highwire
Apr 2022146927Highwire
May 2022136324Highwire
Jun 2022127027Highwire
Jul 2022177117Highwire
Aug 2022126914Highwire
Sep 202298228Highwire
Oct 2022115726Highwire
Nov 2022169432Highwire
Dec 202294016Highwire
Jan 20231112421Highwire
Feb 2023126717Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles